A prospective, randomized, multicenter study evaluating the safety and efficacy of two dosing regimens of daclizumab compared to no antibody induction in simultaneous kidney-pancreas transplantation: Results at 3 years

Transplantation Proceedings

Volumn 37, Issue 8, 2005, Pages 3531-3534

  Stratta, R J ^a,e   Alloway, R R ^b   Lo, A ^c   Hodge, E E ^d  

^a WAKE FOREST UNIVERSITY   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^d Roche Research Laboratories   (United States)

^e WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DACLIZUMAB; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TACROLIMUS;

BACTERIAL INFECTION; BLADDER TUMOR; BRAIN TUMOR; CLINICAL TRIAL; COMPARATIVE STUDY; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DRUG EFFICACY; DRUG SAFETY; GRAFT FAILURE; GRAFT REJECTION; GRAFT SURVIVAL; HOSPITAL ADMISSION; HUMAN; INCIDENCE; INFECTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; OUTCOMES RESEARCH; PANCREAS TRANSPLANTATION; PNEUMONIA; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SQUAMOUS CELL CARCINOMA; URINARY TRACT INFECTION; VOMITING;

ACUTE DISEASE; ANTIBODIES, MONOCLONAL; DIABETES MELLITUS, TYPE 1; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; PANCREAS TRANSPLANTATION; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 27844513856     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2005.09.058     Document Type: Conference Paper

References (10)

1. F. Vincenti, R. Kirkman, S. Light Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation N Engl J Med 338 1998 161
2. B. Nashan, S. Light, I.R. Hardie Daclizumab Double Therapy Study Group Reduction of acute renal allograft rejection by daclizumab Transplantation 67 1999 110
3. H. Ekberg, L. Backman, G. Tufveson Daclizumab prevents acute rejection and improves patient survival post-transplantation 1-year pooled analysis Transpl Int 13 2000 151
4. F. Vincenti, D. Pace, J. Birnbaum Pharmacokinetic and pharmacodynamic studies of one or two doses of daclizumab in renal transplantation Am J Transplant 3 2003 50
5. N. Ahsan, M. Holman, M.V. Jarowenko Limited dose monoclonal IL-2R antibody induction protocol after primary kidney transplantation Am J Transplant 2 2002 568
6. M. Koch, G. Niemeyer, I. Patel Pharmacokinetics, pharmacodynamics, and immunodynamics of daclizumab in a two-dose regimen in liver transplantation Transplantation 73 2002 1640
7. R.J. Stratta, R.R. Alloway, A. Lo Two-dose daclizumab regimen in simultaneous kidney-pancreas transplant recipients primary endpoint analysis of a multicenter, randomized study Transplantation 75 2003 1260
8. G.W. Burke III, D. Kaufman, J.M. Millis Prospective, randomized trial of the effect of antibody induction in simultaneous pancreas and kidney transplantation three-year results Transplantation 77 2004 1269
9. G.L. Bumgardner, I. Hardie, R.W.G. Johnson Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation Transplantation 72 2001 839
10. R. Shapiro, J.B. Young, E.L. Milford Immunosuppression Evolution in practice and trends, 1993-2003 Am J Transplant 5 2005 874